Therapeutic potential of antibodies against interleukin 5 in asthma

Bronchial asthma is characterized by chronic recruitment of eosinophils in the airways. It has been reported that bronchial eosinophil recruitment and activation may even occur in mild-moderate stable asthma and that bronchial epithelium damage and airway responsiveness may be partially associated with the eosinophilic inflammatory reaction.1 There is increasing evidence that the eosinophil-rich bronchial inflammation characteristic of asthma is orchestrated, at least partly,